Eisai, U.S.-Based SuperGen Hit Setback For Leukemia Drug
This article was originally published in PharmAsia News
Executive SummaryEisai's effort to develop a leukemia drug in the United States suffered a setback when its U.S. partner, SuperGen, reported the drug failed to meet clinical trial endpoints
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.